United Laboratories International has been granted a patent for a [1,2,4]triazolo[1,5-a]pyridine compound as a JAK inhibitor for treating diseases related to JAK1 or/and TYK2. The compound, represented by formula (I), its isomers, or pharmaceutically acceptable salts are claimed for use in drug preparation. GlobalData’s report on United Laboratories International gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on United Laboratories International, Pressure swing adsorption was a key innovation area identified from patents. United Laboratories International's grant share as of February 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Jak inhibitor compound for treating jak1/tyk2 related diseases
The granted patent (Publication Number: US11919896B2) discloses a compound of formula (I), its isomers, or pharmaceutically acceptable salts. The compound includes various substituents such as H, F, Cl, Br, I, or CN at different positions denoted by Ra, R1, R2, R3, R4, R5, R6, R7, and R8. Additionally, the compound can be part of a pharmaceutical composition with a carrier for treatment of JAK1 and/or TYK2 related diseases, specifically mentioning rheumatoid arthritis.
The patent claims cover the chemical structure of the compound, the possible substitutions at different positions, and the use of the compound in pharmaceutical compositions for treating specific diseases. The compound's formula allows for flexibility in the selection of substituents, providing potential variations for different applications. The method described involves administering the compound for treating JAK1 and/or TYK2 related diseases, with a specific mention of rheumatoid arthritis as a target condition. Overall, the patent outlines a specific compound structure, its variations, and its application in the treatment of certain diseases, particularly focusing on rheumatoid arthritis as a potential therapeutic target.
To know more about GlobalData’s detailed insights on United Laboratories International, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
